Pacer Advisors Inc. Acquires 565,910 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Pacer Advisors Inc. raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 23,259.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 568,343 shares of the specialty pharmaceutical company's stock after acquiring an additional 565,910 shares during the period. Pacer Advisors Inc. owned approximately 2.70% of ANI Pharmaceuticals worth $33,907,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of ANI Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company's stock valued at $90,314,000 after acquiring an additional 17,460 shares during the period. Dimensional Fund Advisors LP raised its holdings in ANI Pharmaceuticals by 3.5% in the second quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company's stock worth $40,132,000 after purchasing an additional 21,053 shares during the period. Global Alpha Capital Management Ltd. boosted its position in shares of ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its position in shares of ANI Pharmaceuticals by 17.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock worth $13,731,000 after purchasing an additional 34,416 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock valued at $14,651,000 after buying an additional 209,272 shares during the period. Institutional investors own 76.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ANIP. Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research note on Tuesday, October 22nd. StockNews.com lowered shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. HC Wainwright reissued a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective for the company. Finally, Raymond James lifted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $77.33.

ANI Pharmaceuticals Stock Up 1.9 %

Shares of NASDAQ ANIP traded up $1.05 during mid-day trading on Friday, hitting $56.91. The company had a trading volume of 131,831 shares, compared to its average volume of 282,775. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81. The company has a market capitalization of $1.20 billion, a PE ratio of -103.47 and a beta of 0.71. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a 50-day simple moving average of $58.31 and a two-hundred day simple moving average of $60.96.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million for the quarter, compared to analysts' expectations of $144.37 million. During the same quarter in the prior year, the business posted $1.05 EPS. The business's revenue was up 12.5% compared to the same quarter last year. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.